Modelling ecological risks of antiretroviral drugs in the environment

UNAIDS Diallo, 2016, Early diagnosis of HIV infection in infants — one Caribbean and six sub-Saharan African countries, 2011–2015, Morb. Mortal. Wkly Rep., 65, 1285, 10.15585/mmwr.mm6546a2 WHO Justman, 2018, HIV population surveys — bringing precision to the global response, N. Engl. J. Med., 378, 1859, 10.1056/NEJMp1801934 Boskey Opravil, 2002, Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l, AIDS., 16, 1371, 10.1097/00002030-200207050-00009 Watson, 1999, Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1, Pediatr. Infect. Dis. J., 18, 682, 10.1097/00006454-199908000-00006 Weller, 2001, Antiretroviral drugs, BMJ., 322, 1410, 10.1136/bmj.322.7299.1410 Boskey WHO, 2015, Guideline on when to start antiretroviral therapy and pre-exposure prophylaxis for HIV, Bull. World Health Organ., 98, 370 Nachega, 2010, Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy, AIDS Lond. Engl., 24, 1273, 10.1097/QAD.0b013e328339e20e Jewell, 2020, Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models, Lancet HIV, 10.1016/S2352-3018(20)30211-3 Chammartin, 2020, International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019, BMJ Open, 10, 10.1136/bmjopen-2019-035246 Lecher, 2021, HIV viral load monitoring among patients receiving antiretroviral therapy — eight sub-Saharan Africa countries, 2013–2018, MMWR Morb. Mortal. Wkly. Rep., 70, 775, 10.15585/mmwr.mm7021a2 Global Fund Ncube, 2018, Environmental fate and ecotoxicological effects of antiretrovirals: a current global status and future perspectives, Water Res., 145, 231, 10.1016/j.watres.2018.08.017 Wood, 2015, The occurrence of anti-retroviral compounds used for HIV treatment in South African surface water, Environ. Pollut., 199, 235, 10.1016/j.envpol.2015.01.030 Halling-Sørensen, 1998, Occurrence, fate and effects of pharmaceutical substances in the environment- a review, Chemosphere., 36, 357, 10.1016/S0045-6535(97)00354-8 Castellino, 2013, Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans, Antimicrob. Agents Chemother., 57, 3536, 10.1128/AAC.00292-13 Jain, 2013, Occurrence and removal of antiviral drugs in environment: a review, Water Air Soil Pollut., 224, 1410, 10.1007/s11270-012-1410-3 WHO, 2017 Ofrydopoulou, 2021, Sample preparation optimization by central composite design for multi class determination of 172 emerging contaminants in wastewaters and tap water using liquid chromatography high-resolution mass spectrometry, J. Chromatogr. A, 1652, 10.1016/j.chroma.2021.462369 Madikizela, 2020, Analysis, occurrence and removal of pharmaceuticals in African water resources: a current status, J. Environ. Manag., 253, 10.1016/j.jenvman.2019.109741 K’oreje, 2016, Occurrence patterns of pharmaceutical residues in wastewater, surface water and groundwater of Nairobi and Kisumu city, Kenya, Chemosphere., 149, 238, 10.1016/j.chemosphere.2016.01.095 Bärnighausen, 2008, High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study, AIDS., 22, 139, 10.1097/QAD.0b013e3282f2ef43 Justman, 2017, Swaziland HIV incidence measurement survey (SHIMS): a prospective national cohort study, Lancet HIV., 4, e83, 10.1016/S2352-3018(16)30190-4 Vandormael, 2019, Declines in HIV incidence among men and women in a South African population-based cohort, Nat. Commun., 10, 5482, 10.1038/s41467-019-13473-y Keller, 2006, Risk assessment of “down-the-drain” chemicals: search for a suitable model, Sci. Total Environ., 360, 305, 10.1016/j.scitotenv.2005.08.042 Keller, 2014, Worldwide estimation of river concentrations of any chemical originating from sewage-treatment plants using dilution factors, Environ. Toxicol. Chem., 33, 447, 10.1002/etc.2441 ECB Fisher, 2016, The impact of onsite wastewater disposal systems on groundwater in areas inundated by Hurricane Sandy in New York and New Jersey, Mar. Pollut. Bull., 107, 509, 10.1016/j.marpolbul.2016.04.038 Do, 2021, Pharmaceutical contaminants in shallow groundwater and their implication for poor sanitation facilities in low-income countries, Environ. Toxicol. Chem. K’oreje, 2020, Occurrence and treatment of contaminants of emerging concern in the African aquatic environment: literature review and a look ahead, J. Environ. Manag., 254 Ngumba, 2020, Occurrence of antibiotics and antiretroviral drugs in source-separated urine, groundwater, surface water and wastewater in the peri-urban area of Chunga in Lusaka, Zambia, Water SA, 46 UW UNAIDS Gulick, 2003, New antiretroviral drugs, Clin. Microbiol. Infect., 9, 186, 10.1046/j.1469-0691.2003.00570.x Etoori, 2018, Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland, J. Int. AIDS Soc., 21, 10.1002/jia2.25194 EMA, 2018, Environmental risk assessment of medicinal products for human use, Eur. Med. Agency. UNFPA, Swaziland releases population count from 2017 census, UNFPA Kingd. Eswatini. (2017). https://eswatini.unfpa.org/en/news/swaziland-releases-population-count-2017-census (accessed October 17, 2022). Mabuza, 2017, History of the HIV epidemic and response in Swaziland, Afr. J. AIDS Res., 16, v, 10.2989/16085906.2017.1402493 Woldesenbet, 2022, Progress towards the UNAIDS 95-95-95 targets among pregnant women in South Africa: results from the 2017 and 2019 national antenatal HIV sentinel surveys, PLoS One, 17, 10.1371/journal.pone.0271564 Keene, 2021, Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study, AIDS Lond. Engl., 35, 1423, 10.1097/QAD.0000000000002936 Rakhmanina, 2010, Efavirenz in the therapy of HIV infection, Expert Opin. Drug Metab. Toxicol., 6, 95, 10.1517/17425250903483207 Collier, 1993, Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection, Ann. Intern. Med., 119, 786, 10.7326/0003-4819-119-8-199310150-00003 Collier, 2004, Human placental glucuronidation and transport of 3’azido-3′-deoxythymidine and uridine diphosphate glucuronic acid, Drug Metab. Dispos., 32, 813, 10.1124/dmd.32.8.813 Bancheno, 2010, Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, southern Africa, AIDS Care, 22, 1130, 10.1080/09540121003615079 DiCarlo, 2019, Healthcare worker experiences with option B+ for prevention of mother-to-child HIV transmission in eSwatini: findings from a two-year follow-up study, BMC Health Serv. Res., 19, 210, 10.1186/s12913-019-3997-1 Parker, 2015, Implementation and operational research: barriers and facilitators to combined ART initiation in pregnant women with HIV: lessons learnt from a PMTCT B+ pilot program in Swaziland, J. Acquir. Immune Defic. Syndr., 1999, e24, 10.1097/QAI.0000000000000537 Libório, 2008, Rosiglitazone reverses tenofovir-induced nephrotoxicity, Kidney Int., 74, 910, 10.1038/ki.2008.252 Davies, 2018, Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding, Sex. Health, 15, 501, 10.1071/SH18067 Eakle, 2018, Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: can it change the game?, Retrovirology., 15, 29, 10.1186/s12977-018-0408-3 Heald, 1996, Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction, Antimicrob. Agents Chemother., 40, 1514, 10.1128/AAC.40.6.1514 Moore, 1999, The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1, AIDS., 13, 2239, 10.1097/00002030-199911120-00006 Mesplède, 2014, Is resistance to dolutegravir possible when this drug is used in first-line therapy?, Viruses., 6, 3377, 10.3390/v6093377 Venter, 2017, Cutting the cost of South African antiretroviral therapy using newer, safer drugs, SAMJ South Afr. Med. J., 107, 28, 10.7196/SAMJ.2017.v107i1.12058 Dooley, 2013, Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects, JAIDS J. Acquir. Immune Defic. Syndr., 62, 21, 10.1097/QAI.0b013e318276cda9 Castellino, 2013, Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans, Antimicrob. Agents Chemother., 57, 3536, 10.1128/AAC.00292-13 Kim, 2017, A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects, Drug Des. Dev. Ther., 11, 3171, 10.2147/DDDT.S149125 Riska, 1999, Disposition and biotransformation of the antiretroviral drug nevirapine in humans, Drug Metab. Dispos., 27, 895 Cvetkovic, 2003, Lopinavir/Ritonavir, Drugs., 63, 769, 10.2165/00003495-200363080-00004 Singlas, 1992, Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis, Antimicrob. Agents Chemother., 36, 1519, 10.1128/AAC.36.7.1519 Milburn, 2017, Renal effects of novel antiretroviral drugs, Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc., 32, 434 Nannou, 2020, Antiviral drugs in aquatic environment and wastewater treatment plants: a review on occurrence, fate, removal and ecotoxicity, Sci. Total Environ., 699, 10.1016/j.scitotenv.2019.134322 Hernando, 2006, Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments, Talanta., 69, 334, 10.1016/j.talanta.2005.09.037 Ngumba, 2016, Occurrence of selected antibiotics and antiretroviral drugs in Nairobi River Basin, Kenya, Sci. Total Environ., 539, 206, 10.1016/j.scitotenv.2015.08.139 Almeida, 2021, Chronic toxicity and environmental risk assessment of antivirals in Ceriodaphnia dubia and Raphidocelis subcapitata, Water Sci. Technol., 84, 1623, 10.2166/wst.2021.347 Guo, 2015, Do pharmaceuticals pose a threat to primary producers?, Crit. Rev. Environ. Sci. Technol., 45, 2565, 10.1080/10643389.2015.1061873 Robson, 2017, The potential effects of efavirenz on Oreochromis mossambicus after acute exposure, Environ. Toxicol. Pharmacol., 56, 225, 10.1016/j.etap.2017.09.017 Boesecke, 2008, Toxicity of HIV protease inhibitors: clinical considerations, Curr. Opin. HIV AIDS., 3, 653, 10.1097/COH.0b013e328312c392 Lv, 2015, HIV protease inhibitors: a review of molecular selectivity and toxicity, HIVAIDS Auckl. NZ., 7, 95 Vanangamudi, 2020, Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens, Curr. Opin. Pharmacol., 54, 179, 10.1016/j.coph.2020.10.009 Silva, 2019, Toxicity for aquatic organisms of antiretroviral tenofovir disoproxil, J. Environ. Prot., 10, 1565, 10.4236/jep.2019.1012093 Omotola, 2021, Environmental risk characterization of an antiretroviral (ARV) lamivudine in ecosystems, Int. J. Environ. Res. Public Health, 18, 8358, 10.3390/ijerph18168358 K’oreje, 2012, From multi-residue screening to target analysis of pharmaceuticals in water: development of a new approach based on magnetic sector mass spectrometry and application in the Nairobi River basin, Kenya, Sci. Total Environ., 437, 153, 10.1016/j.scitotenv.2012.07.052 Abafe, 2018, LC-MS/MS determination of antiretroviral drugs in influents and effluents from wastewater treatment plants in KwaZulu-Natal, South Africa, Chemosphere., 200, 660, 10.1016/j.chemosphere.2018.02.105 Mlunguza, 2020, Determination of selected antiretroviral drugs in wastewater, surface water and aquatic plants using hollow fibre liquid phase microextraction and liquid chromatography - tandem mass spectrometry, J. Hazard. Mater., 382, 10.1016/j.jhazmat.2019.121067 Schoeman, 2015, Quantification of selected antiretroviral drugs in a wastewater treatment works in South Africa using GC-TOFMS, J. Chromatogr. Sep. Tech., 06 Musee, 2021, Occurrence, fate, effects, and risks of dexamethasone: ecological implications post-COVID-19, Int. J. Environ. Res. Public Health, 18, 11291, 10.3390/ijerph182111291 Kasprzyk-Hordern, 2009, The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters, Water Res., 43, 363, 10.1016/j.watres.2008.10.047 Kumar, 2013, Development of solid self emulsifying drug delivery systems containing efavirenz: in vitro and in vivo evaluation, Int. J. Pharma Bio Sci., 4, 869 Kasim, 2004, Molecular properties of WHO essential drugs and provisional biopharmaceutical classification, Mol. Pharm., 1, 85, 10.1021/mp034006h Mtolo, 2019, Synthesis and application of a molecularly imprinted polymer in selective solid-phase extraction of efavirenz from water, Water Sci. Technol., 79, 356, 10.2166/wst.2019.054 Kebede, 2020, Adsorption of antiretroviral (ARVs) and related drugs from environmental wastewaters using nanofibers, J. Environ. Chem. Eng., 8, 10.1016/j.jece.2020.104049 Peng, 2014, Profile and behavior of antiviral drugs in aquatic environments of the Pearl River Delta, China, Sci. Total Environ., 466–467, 755, 10.1016/j.scitotenv.2013.07.062 Kamara, 2019, Understanding disaster resilience in communities affected by recurrent drought in Lesotho and Swaziland—a qualitative study, PLoS One, 14, 10.1371/journal.pone.0212994 Manyatsi, 2015, Evaluation of satellite rainfall estimates for Swaziland, Am. J. Agric. For., 3, 93 UNICEF Eswatini Mukui, 2016, Rates and predictors of non-adherence to antiretroviral therapy among HIV-positive individuals in Kenya: results from the second Kenya AIDS indicator survey, 2012, PLoS One, 11, 10.1371/journal.pone.0167465 Corburn, 2016, Informal settlements and a relational view of health in Nairobi, Kenya: sanitation, gender and dignity, Health Promot. Int., 31, 258, 10.1093/heapro/dau100 Lagerkvist, 2013, Health in perspective: framing motivational factors for personal sanitation in urban slums in Nairobi, Kenya, using anchored best–worst scaling, J. Water Sanit. Hyg. Dev., 4, 108, 10.2166/washdev.2013.069 Lemly, 1996, Evaluation of the Hazard quotient method for risk assessment of selenium, Ecotoxicol. Environ. Saf., 35, 156, 10.1006/eesa.1996.0095 Jonker, 2016, Determining octanol-water partition coefficients for extremely hydrophobic chemicals by combining “slow stirring” and solid-phase microextraction, Environ. Toxicol. Chem., 35, 1371, 10.1002/etc.3300 Escher, 2011, Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater, Water Res., 45, 75, 10.1016/j.watres.2010.08.019 Kumari, 2021, Can pharmaceutical drugs used to treat Covid-19 infection leads to human health risk? A hypothetical study to identify potential risk, Sci. Total Environ., 778, 10.1016/j.scitotenv.2021.146303 Collins, 2019, Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration, Lancet HIV., 6, e105, 10.1016/S2352-3018(18)30319-9 Muriuki, 2020, Occurrence, distribution, and risk assessment of pharmerciuticals in wastewater and open surface drains of peri-urban areas: case study of Juja town, Kenya, Environ. Pollut., 267, 10.1016/j.envpol.2020.115503 Silva, 2019, Toxicity for aquatic organisms of antiretroviral tenofovir disoproxil, J. Environ. Prot., 10, 1565, 10.4236/jep.2019.1012093 Altman, 1995, Absence of evidence is not evidence of absence, BMJ., 311, 485, 10.1136/bmj.311.7003.485 Mlenga, 2016, Towards community resilience, focus on a rural water supply, sanitation and hygiene project in Swaziland, Am. J. Rural Dev., 4, 85 Reddy, 2021, Algae-mediated processes for the treatment of antiretroviral drugs in wastewater: prospects and challenges, Chemosphere., 280, 10.1016/j.chemosphere.2021.130674 Aslam, 2018, Antibiotic resistance: a rundown of a global crisis, Infect. Drug Resist., 11, 1645, 10.2147/IDR.S173867 Chokshi, 2019, Global contributors to antibiotic resistance, J. Glob. Infect. Dis., 11, 36, 10.4103/jgid.jgid_110_18 Boxall, 2012, Pharmaceuticals and personal care products in the environment: what are the big questions?, Environ. Health Perspect., 120, 1221, 10.1289/ehp.1104477